What are the latest updates to small cell lung cancer (SCLC) treatment?

Latest Updates in Small Cell Lung Cancer Treatment

The most significant recent advances in SCLC treatment are the FDA approval of tarlatamab for relapsed disease and the establishment of consolidation durvalumab as standard of care for limited-stage SCLC after chemoradiotherapy. 1

Limited-Stage SCLC: Consolidation Immunotherapy

Patients with LS-SCLC who complete concurrent chemoradiotherapy without disease progression should receive consolidation durvalumab for up to 2 years (unless contraindications to immunotherapy exist). 1

Key Evidence and Outcomes:

• The ADRIATIC trial demonstrated that adding consolidation durvalumab improves 2-year overall survival by approximately 10% compared to chemoradiotherapy alone (68.5% vs 58.5%). 1
• This represents a new standard of care, with moderate evidence quality and strong recommendation strength. 1
• Even patients with ECOG PS 3-4 who improve after chemoradiotherapy may be offered durvalumab consolidation, though this carries a conditional recommendation based on lower quality evidence. 1

Important Safety Considerations:

• Immune-related adverse events occurred in 32.1% of durvalumab patients versus 10.2% with placebo. 1
• Pneumonitis rates were higher (38.2% vs 30.2% any grade). 1
• Drug discontinuation due to adverse events occurred in 16.4% versus 10.6% with placebo. 1

Relapsed SCLC: Tarlatamab as New Standard Option

Tarlatamab, a bispecific T-cell engager targeting DLL3 and CD3, was FDA-approved in May 2024 and now joins topotecan and lurbinectedin as preferred agents for relapsed SCLC. 1

Efficacy Profile:

• Overall response rate: 40% with median duration of response of 9.7 months—substantially longer than other available agents. 1
• Response rates: 52% in platinum-resistant disease, 31% in platinum-sensitive disease. 1
• Median PFS: 4.9 months; 9-month OS rate: 68%. 1
• Eligible patients had received ≥2 prior systemic regimens (including platinum-based therapy), with 73% having prior immunotherapy. 1

Dosing and Administration:

• Initial dose: 1 mg IV on day 1 of cycle 1. 1
• Step-up dosing: 10 mg on days 8 and 15 of cycle 1. 1
• Maintenance: 10 mg every 2 weeks thereafter until progression or unacceptable toxicity. 1

Critical Safety Management:

• Inpatient monitoring is mandatory for 24 hours after the first two doses (days 1 and 8 of cycle 1) due to risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). 1
• CRS occurred in 51% of patients (mostly grade 1-2; only 1% grade 3), with median onset at 13 hours and duration of 4 days. 1
• ICANS occurred in 8% (all grade 1-2), with median onset at 5 days. 1
• Nearly all CRS and ICANS events occurred during cycle 1. 1
• Grade ≥3 treatment-related adverse events: 26% overall, but severe CRS and ICANS were rare (1% and 0%, respectively). 1

Exclusion Criteria:

Tarlatamab should not be used in patients with: 1

• Interstitial lung disease or active pneumonitis
• History of severe immune-related adverse events
• Grade ≥2 pneumonitis from prior immunotherapy
• History of severe infusion reactions

Treatment Algorithm for Relapsed SCLC

Chemotherapy-Free Interval <90 Days (Platinum-Resistant):

Single-agent systemic therapy is preferred over multiagent regimens due to better risk-benefit balance. Preferred agents are topotecan, lurbinectedin, or tarlatamab. 1

Chemotherapy-Free Interval ≥90 Days (Platinum-Sensitive):

Either rechallenge with platinum-based regimen OR single-agent therapy (topotecan, lurbinectedin, or tarlatamab) may be offered. 1

Extensive-Stage SCLC: First-Line Standard

First-line therapy should consist of carboplatin or cisplatin plus etoposide combined with immunotherapy (atezolizumab or durvalumab), followed by maintenance immunotherapy in patients without contraindications. 1

This represents a paradigm shift from chemotherapy alone, with high-quality evidence supporting improved overall survival. 1, 2, 3

Important Clinical Considerations

Sequencing Uncertainty:

Currently, no head-to-head data exist comparing tarlatamab, lurbinectedin, and topotecan to guide optimal sequencing in relapsed disease. 1 The ongoing DeLLphi-304 trial is comparing tarlatamab with standard chemotherapy to address this question. 1

Cross-Trial Comparisons:

While cross-trial comparisons suggest both lurbinectedin and tarlatamab are more effective than topotecan, tarlatamab's duration of response exceeding 9 months is notably superior to other agents. 1

Common Pitfall:

Do not delay initiating tarlatamab due to concerns about toxicity—the severe (grade ≥3) rates of CRS and ICANS are extremely low (1% and 0%) with the recommended 10 mg dose and step-up dosing strategy. 1 The key is ensuring appropriate inpatient monitoring during cycle 1. 1